Day 3: New treatment options for endocrine therapy in metastatic breast cancer

Day 3 at the San Antonio Breast Cancer Symposium (SABCS) focused on endocrine treatment in metastatic breast cancer, specifically exploring new treatment options for endocrine therapy after progression in first-line treatment.

Prof dr Hannelore Denys from the University Hospital in Ghent made a summary of the most important presentations in this general session. New treatment options for endocrine therapy were discussed in the SERENA-2 trial with camizestrant. Prof Denys also presented updated results of the EMERALD phase 3 trial by duration of prior CDK4/6i in the metastatic setting. The phase III CAPItello-291 trial with capivasertib and fulvestrant for patients with aromatase inhibitor-resistant ER+/HER2- advanced breast cancer is also summarised. She concluded with the phase II PACE study evaluating fulvestrant, palbociclib and avelumab for endocrine pre-treated ER+/HER2- metastatic breast cancer.